阿拉基酸代谢作为AKI到CKD过渡中的治疗点
Xiao-Jun Li1,2, Ping Suo1, Yan-Ni Wang1
1School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Frontiers in pharmacology
|March 25, 2024
概括
阿拉基酸 (AA) 和其代谢物在功能和疾病中至关重要. 了解它们的通路可能会揭示损伤和慢性病的新治疗点.
科学领域:
- 生物化学 生物化学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
背景情况:
- 阿拉基酸 (AA) 是一个关键的细胞膜脂质.
- AA的新陈代谢涉及循环氧化酶 (COX),脂氧化酶 (LOX) 和细胞染色体P450 (CYP450) 途径.
- 病的发病包括氧化应激,亡,炎症和纤维化.
研究的目的:
- 审查阿拉基酸 (AA) 的三个主要代谢途径.
- 讨论AA代谢物在病中的分子机制.
- 探索AA和eicosanoids作为潜在的生物标志物和治疗点.
主要方法:
- 关于阿拉基酸代谢的文献综述.
- 在病理生理学中分析分子机制.
- 讨论AA在急性损伤 (AKI),糖尿病病 (DN) 和细胞癌 (RCC) 中的作用.
主要成果:
- 包括前列腺素和白血在内的AA代谢物参与脏生理学和病理学.
- 在病中,AA途径与氧化应激,炎症和纤维化有关.
- 氨基酸及其衍生物显示出作为病进展的生物标志物的潜力.
结论:
- 阿拉基酸代谢显著影响功能和疾病.
- 向AA途径为脏疾病提供了潜在的治疗策略.
- 对AA代谢物的进一步研究可能有助于识别AKI到CKD连续.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Antihypertensive Drugs: Direct Renin Inhibitors
616
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
616
Phase II Reactions: Acetylation Reactions
223
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
223
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
627
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
162
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
162
Antihypertensive Drugs: Angiotensin II Receptor Blockers
720
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720


